Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Common Equity: 2011-2024

Historic Common Equity for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $349.0 million.

  • Adma Biologics' Common Equity rose 85.94% to $431.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $431.2 million, marking a year-over-year increase of 85.94%. This contributed to the annual value of $349.0 million for FY2024, which is 158.14% up from last year.
  • According to the latest figures from FY2024, Adma Biologics' Common Equity is $349.0 million, which was up 158.14% from $135.2 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Common Equity ranged from a high of $349.0 million in FY2024 and a low of $88.2 million during FY2020.
  • Its 3-year average for Common Equity is $212.1 million, with a median of $152.0 million in 2022.
  • In the last 5 years, Adma Biologics' Common Equity dropped by 11.03% in 2023 and then skyrocketed by 158.14% in 2024.
  • Yearly analysis of 5 years shows Adma Biologics' Common Equity stood at $88.2 million in 2020, then spiked by 59.97% to $141.2 million in 2021, then increased by 7.65% to $152.0 million in 2022, then fell by 11.03% to $135.2 million in 2023, then surged by 158.14% to $349.0 million in 2024.